This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Hanmi Selects The Medidata Clinical Cloud For Faster Data Capture And Better Operational Oversight Of Clinical Trials

The Medidata Solutions (NASDAQ: MDSO) platform has been selected by Hanmi Pharmaceutical Co., Ltd., a leading Korean pharmaceutical company, to support data collection and management in Phase I and II oncology clinical trials. Following a recommendation from LSK Global PS, a Medidata Services Partner and Korean contract research organization (CRO) providing clinical trial services to Hanmi, the life science organization selected the industry-leading Medidata Rave ® system for electronic data capture, management and reporting.

Hanmi’s choice of the Medidata Clinical Cloud™ supports the company’s wider initiative to improve workflows and productivity while developing new therapies. In particular, Hanmi anticipates that its use of Rave will enhance site productivity through real-time data entry in an intuitive user interface and will also help streamline trials through Rave’s timely reporting capabilities and smooth handling of mid-study protocol amendments.
  • “Hanmi’s commitment to efficiently providing new innovative drugs across a number of therapeutic areas is reinforced by their adoption of the Medidata Clinical Cloud,” said Glen de Vries, president, Medidata Solutions. “By tapping into the effectiveness of next generation technologies, Hanmi is showing its dedication to safely expedite R&D to help bring drugs to waiting patients faster.”

By implementing Rave, the company also anticipates that more timely access to data for analysis will support better trial oversight and more informed and earlier decision making. Additionally, Hanmi anticipates better study start-up through Rave’s reusable study assets and its standards-based integration framework that facilitates rapid integrations with other systems to enable data sharing.
  • “Medidata’s reputation for streamlining clinical trials and enhancing trial decision making was a major factor in our decision to select the Medidata platform,” said Jeewoong Son, senior vice president, Hanmi. “Medidata’s commitment to designing cloud-based solutions that enhance research team productivity through user-friendly interfaces will play a role in driving efficiencies in our drug development programs and reducing the total cost of our clinical development.”

Connect with Medidata:

About Hanmi Pharmaceutical Co., Ltd.

Established in 1973, Hanmi Pharmaceuticals now is one of the top 5 pharmaceutical companies in Korea, and has been the most R&D focused company with the highest R&D investment for several years. Hanmi Pharma also has worldwide offices in major countries including China, Japan, Europe and the U.S. Hanmi has been successful for a few decades with high flexibility, continuously changing its market and development strategy from first generics to IMD & FDC (Incrementally Modified Drug and Fixed Dose Combination), and to new drug developments including innovative small molecules and biologics. It has more than 10 FDC pipelines including collaboration projects with MSD, GSK and Sanofi. During the period of open innovation, it made multiple strategic collaborations with multinational companies and biotech companies. Hanmi is actively conducting clinical trials for new drug pipelines such as biobetter drugs with LAPSCOVERY (Long Acting Protein-Peptide Discovery Platform Technology) and small molecule oncology pipelines in the global market.

About Medidata Solutions Worldwide

Medidata Solutions is a leading global provider of cloud-based clinical development solutions that enhance the efficiency of customers' clinical trials. Medidata's advanced platform lowers the total cost of clinical development by optimizing clinical trials from concept to conclusion: from study and protocol design, trial planning and budgeting, site negotiation, clinical portal, trial management, randomization and trial supply management, clinical data capture and management, safety events capture, medical coding to business analytics. Our diverse life science customer base spans biopharmaceutical companies, medical device and diagnostic companies, academic and government institutions, CROs and other research organizations, and includes more than 20 of the top 25 global pharmaceutical companies as well as organizations of all sizes developing life-enhancing medical treatments and diagnostics.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $93.21 -0.44%
FB $117.80 -0.22%
GOOG $701.26 0.80%
TSLA $211.34 -5.00%
YHOO $36.94 2.60%


Chart of I:DJI
DOW 17,660.71 +9.45 0.05%
S&P 500 2,050.63 -0.49 -0.02%
NASDAQ 4,717.0940 -8.5450 -0.18%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs